p53: the tumour suppressor
Widely dubbed ‘the guardian of the genome’, the protein p53 provides important protection against cancer — when it is active, that is. Many malignant cells exhibit p53 dysfunction, and several clinical trials of agents intended to restore p53 to working order are now under way.
This Nature Outline is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support of Boehringer Ingelheim in producing this Outline. The sponsor retains the sole responsibility for the following message.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Central to our aim to improve human health is our commitment to oncology research. At Boehringer Ingelheim Oncology, we are giving patients new hope by taking cancer on. We are dedicated to collaborating with the oncology community to deliver breakthrough treatments, faster. We are committed to our focus disease areas of lung and gastrointestinal cancers but are guided by science and pursue opportunities in other areas of unmet need, to deliver first-in-class treatments that can transform patient lives. Our commitment to innovation has resulted in pioneering treatments and we are advancing a unique pipeline of cancer cell directed agents, immuno-oncology therapies and combination approaches to help win the fight against cancer.
Learn more at www.boehringer-ingelheim.com
